ArticleFrontiers in medicine2025
A controlled study of Gd-EOB-DTPA-enhanced MRI compared with enhanced CT in assessing lesion status after TACE for hepatocellular carcinoma.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the diagnostic capability of Gd-EOB-DTPA-enhanced MRI in assessing lesion status following transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), in comparison to contrast-enhanced CT (CECT). Methods: A total of 56 patients with HCC who underwent Gd-EOB-DTPA-enhanced MRI and CECT scans post-TACE were initially enrolled. The ability of both imaging modalities to differentiate between surviving, new, or necrotic lesions was assessed, using digital subtraction angiography (DSA) or interventional diagnostic results as the reference standard. Detection rates were compared using the chi-square test, while sensitivity, specificity, and accuracy were analyzed with McNemar's test. Results: After applying inclusion and exclusion criteria, 48 patients were eventually included in the analysis. The reference standard identified 14 cases of surviving lesions, 19 of new lesions, and 15 of necrotic lesions. Gd-EOB-DTPA-enhanced MRI demonstrated a sensitivity of 93.9% (31/33), specificity of 100% (15/15), and a Youden index of 0.939, whereas CECT exhibited a sensitivity of 51.5% (17/33), specificity of 60.0% (9/15), and a Youden index of 0.115. Conclusion: The findings indicate that Gd-EOB-DTPA-enhanced MRI possesses superior diagnostic value for evaluating lesion status in HCC post-TACE compared to CECT, as evidenced by significant differences in sensitivity and specificity (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.